Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Lupin Australia Pty Limited

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (297)
ARTG (242)
Prescription medicine registration (23)

Date

2025 (18)
2024 (49)
2023 (48)
2022 (222)
2021 (8)
2020 (33)
2019 (21)
2018 (32)
2017 (11)
2016 (10)
2014 (27)
2013 (14)
2012 (2)
2011 (16)
2010 (19)
2009 (1)
2008 (21)
2007 (5)
2001 (1)
1991 (4)

Search

Sponsor content

562 result(s) found, displaying 51 to 60

SUGAMMADEX LAPL sugammadex (as sodium) 200 mg/2 mL solution for injection vial (395864)

1 November 2023

ARTG

Australian Register of Therapeutic Goods (ARTG) information for SUGAMMADEX LAPL sugammadex (as sodium) 200 mg/2 mL solution for injection vial.
SUGAMMADEX LAPL sugammadex (as sodium) 500 mg/5 mL solution for injection vial (395861)

1 November 2023

ARTG

Australian Register of Therapeutic Goods (ARTG) information for SUGAMMADEX LAPL sugammadex (as sodium) 500 mg/5 mL solution for injection vial.
RIVAROXABAN GH rivaroxaban 20 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
RIVAROXABAN GH rivaroxaban 15 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
RIVAROXABAN GH rivaroxaban 10 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
RIVAROXABAN GH rivaroxaban 2.5 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
FENOFIBRATE GENERICHEALTH fenofibrate 145 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
FENOFIBRATE GENERICHEALTH fenofibrate 48 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
SUGAMMADEX GH sugammadex (as sodium) 500 mg/5 mL solution for injection vial Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
SUGAMMADEX GH sugammadex (as sodium) 200 mg/2 mL solution for injection vial Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited

Pages

First page
Previous page
…
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Page 8
Page 9
Page 10
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.